Answers are grounded in this paper and cite their sources.
Demonstrates reduced disease severity in murine dermatitis, indicating potential therapeutic benefits of polyhexanide.
METHODS: exposure protocol, with confirmation of IL-36 protein expression. Animals were treated topically with GX03 or left untreated. Disease severity was assessed with blinded investigator global assessment scoring using the validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD). CONCLUSIONS: These findings suggest that extended-release topical polyhexanide (GX03) reduces disease severity in a murine dermatitis model characterized by IL-36 expression.
No takes yet. Share an insight, caveat, or question.
Burnam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: